【摘要】 目的:观察奥沙利铂(Oxaliplatin,L-OHP)联合卡培他滨(Capecitabine,CAPE)治疗高龄晚期贲门癌(Gas-tric cardiac adenocarcinoma,GCA)的疗效和安全性。方法:80例GCA患者,根据年龄分为高龄组(≥75岁)38例和对照组(<75岁)42例,均采用XELOX方案化疗,即L-OHP 65mg/m2静脉滴注2h,d1、d8,CAPE1000mg/m2口服,2次/天,d1～d14,21天为1个周期,连续4～6个周期。化疗2个周期后评价肿瘤化疗敏感性和吞咽困难改善情况;化疗结束4周后进行近期疗效和不良反应评价。结果:高龄组和对照组比较,化疗敏感性分别为76.3%(29/38)和78.6%(33/42),无显著性差异(χ2=0.058,P>0.05);吞咽困难改善率分别为86.8%(33/38)和81.0%(34/42),无显著性差异(χ2=0.509,P>0.05);两组近期疗效分别为78.9%(30/38)和78.6%(33/42),无显著性差异(χ2=0.002,P>0.05);两组不良反应均为可逆,两组相比无显著性差异(P>0.05)。结论:L-OHP联合CAPE治疗高龄晚期GCA疗效较好,改善症状快,不良反应患者可以耐受。更多还原

【Abstract】 Objective: To evaluate the effects and safety of Oxaliplatin(L-OHP) combined with Capecitabine(CAPE) in older patients with advanced gastric cardiac adenocarcinoma(GCA). Methods: Eighty patients with advanced GCA were classified into the older group(≥75 years) and the control group(<75 years). XELOX regimen was administered in both groups, i.e. L-OHP 65 mg/m2 iv infusion 2h on d1 and d8; CAPE 1000mg/m2/d twice daily from d1 to d14. The regimen was given for 4-6 cycles, with 21 days in each cycle. Patient response and swallow status were evaluated after 2 cycles (6 weeks). The effects and toxicity were assessed at 4 weeks after the chemotherapy regimen was completed. Results: The response rate was 76.3%(29/38) in the older group and 78.6%(33/42) in the control group(χ2=0.058, P>0.05). The rate of swallow improvement was 86.8%(33/38) in the older group and 81.0% (34/42) in the control group (χ2=0.509, P>0.05). The efficacy was 78.9%(30/38) in the older group and 78.6%(33/42) in the control group(χ2=0.002, P>0.05). The toxicity was similar and reversible in both groups(P>0.05). Conclusion: Combination chemotherapy of L-OHP plus CAPE is an effective, safe and well-tolerated regimen for treating older patients with advanced GCA.更多还原